S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
NASDAQ:ALKS

Alkermes - ALKS Stock Forecast, Price & News

$26.45
-0.15 (-0.56%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.04
$26.80
50-Day Range
$25.17
$31.87
52-Week Range
$21.24
$33.00
Volume
960,632 shs
Average Volume
1.81 million shs
Market Capitalization
$4.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.10

Alkermes MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
13.8% Upside
$30.10 Price Target
Short Interest
Bearish
4.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
0.46mentions of Alkermes in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$211,215 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.35) to ($0.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

874th out of 1,124 stocks

Pharmaceutical Preparations Industry

445th out of 555 stocks

ALKS stock logo

About Alkermes (NASDAQ:ALKS) Stock

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ALKS. Piper Sandler assumed coverage on Alkermes in a report on Tuesday. They issued a "neutral" rating and a $26.00 price target on the stock. HC Wainwright increased their target price on Alkermes from $30.00 to $32.00 in a report on Thursday, April 28th. StockNews.com upgraded Alkermes from a "buy" rating to a "strong-buy" rating in a report on Thursday, July 28th. The Goldman Sachs Group began coverage on Alkermes in a research note on Wednesday, April 20th. They set a "buy" rating and a $35.00 price target on the stock. Finally, Stifel Nicolaus increased their price target on Alkermes to $28.00 in a research note on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $30.10.

Alkermes Trading Down 0.6 %

Shares of ALKS opened at $26.45 on Wednesday. The company has a current ratio of 2.39, a quick ratio of 2.03 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $4.34 billion, a P/E ratio of -46.40 and a beta of 0.60. The stock's fifty day simple moving average is $28.42 and its 200 day simple moving average is $27.44. Alkermes has a twelve month low of $21.24 and a twelve month high of $33.00.

Alkermes (NASDAQ:ALKS - Get Rating) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.05. Alkermes had a positive return on equity of 0.79% and a negative net margin of 8.02%. The firm had revenue of $276.22 million during the quarter, compared to the consensus estimate of $269.01 million. During the same period in the prior year, the firm earned $0.13 EPS. The firm's quarterly revenue was down 9.1% compared to the same quarter last year. On average, equities research analysts forecast that Alkermes will post -0.35 earnings per share for the current year.

Insider Activity at Alkermes

In related news, SVP Christian Todd Nichols sold 7,474 shares of the stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $28.26, for a total value of $211,215.24. Following the completion of the sale, the senior vice president now directly owns 21,035 shares in the company, valued at approximately $594,449.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.76% of the stock is owned by insiders.

Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Stock News Headlines

Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Company Calendar

Last Earnings
7/27/2022
Today
8/17/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,211
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$30.10
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+13.8%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$-48,170,000.00
Pretax Margin
-8.91%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$0.73 per share
Book Value
$6.59 per share

Miscellaneous

Free Float
156,436,000
Market Cap
$4.34 billion
Optionable
Optionable
Beta
0.60

Social Links















ALKS Stock - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price forecast for 2022?

10 brokers have issued 12-month price targets for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they expect the company's share price to reach $30.10 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2022?

Alkermes' stock was trading at $23.26 at the beginning of 2022. Since then, ALKS stock has increased by 13.7% and is now trading at $26.45.
View the best growth stocks for 2022 here
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) issued its earnings results on Wednesday, July, 27th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.05. The business earned $276.22 million during the quarter, compared to the consensus estimate of $269.01 million. Alkermes had a positive trailing twelve-month return on equity of 0.79% and a negative net margin of 8.02%. Alkermes's revenue was down 9.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.13 EPS.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $0.09-$0.27 for the period, compared to the consensus estimate of $0.04. The company issued revenue guidance of $1.05 billion-$1.12 billion, compared to the consensus revenue estimate of $1.09 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.36%), State Street Corp (3.60%), Primecap Management Co. CA (3.28%), Hardman Johnston Global Advisors LLC (3.26%), Renaissance Technologies LLC (3.24%) and Artisan Partners Limited Partnership (1.21%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $26.45.

How much money does Alkermes make?

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.34 billion and generates $1.17 billion in revenue each year. The company earns $-48,170,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Alkermes have?

The company employs 2,211 workers across the globe.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
When was Alkermes founded?

Alkermes was founded in 1987.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.

This page (NASDAQ:ALKS) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.